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I. The evaluation and the need for an EU Action Plan on drugs for 2017-2020  
The EU's Drugs Strategy 2013-2020
1
 and its first Action Plan on Drugs 2013-2016
2
  set out a 
political framework and priorities for the EU’s drugs policy. The Strategy provides a single, 
evidence-based framework for tackling drugs inside and outside the EU, and is based on a 
five pillar structure consisting of:  
 two main policy areas  
 the reduction of the drug demand and  
 the reduction of drug supply;  
 and three cross-cutting themes:  
 coordination,  
 international cooperation and  
 research, information, monitoring and evaluation.  
The Strategy requires the Commission to "initiate an external midterm assessment of the 
Strategy by 2016, in view of preparing a second Action Plan for the period 2017-2020". The 
European Agenda on Security
3
 provides for the Commission to assess progress in 
implementing the 2013-2016 Action Plan and decide on that basis whether to propose a new 
Action Plan for 2017-2020. 
With the support of an external contractor
4
, the Commission conducted the mid-term 
assessment of the Strategy and the final evaluation of the Action Plan between April and 
November 2016
5
. Due to their complementarity and interconnection, these are presented in 
the form of a single, comprehensive evaluation. 
This Communication sets out the results of the evaluation
6
 and proposes the steps to be taken 
next. In view of the overall findings of the evaluation, the Commission has decided to propose 
a new Action Plan for the period 2017-2020. Building on the results of the evaluation, and 
given that the strategic framework will not change before 2020, the new proposed Action Plan 
is an updated version of the EU Action Plan on Drugs 2013-2016 with a number of 
modifications. It reflects the findings and the recommendations of the assessment that the 
Commission found pertinent as well as a number of additional actions to address new and 
emerging priorities which have not been sufficiently covered by the previous Action Plan, but 
are relevant in light of challenges EU Member States are currently facing. The Commission's 
proposed draft Action Plan on drugs for 2017-2020 is set out in the annex below
7
.  
                                                            
1  OJ C 402, 29.12.2012, p. 1. 
2  OJ C 351, 30.11.2013, p. 1. 
3  COM(2015) 185. 
4  A consortium composed of Ernst & Young and RAND Europe.  
5  http://ec.europa.eu/dgs/home-affairs/what-is-new/work-in-progress/initiatives/984ws_intro_en.htm  
6  An overview of the results of the evaluation in the form of a Commission Staff Working Document is 
annexed to this Communication - SWD (2017)95. 
7  It is not the objective of this Communication to update the EU Drugs Strategy, which remains valid 
until 2020. The Commission considers that the changes proposed in the new draft Action Plan are in 
line with the existing Strategy. 
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II. Context 
The market for illicit drugs is the most dynamic criminal market, as confirmed also in the 
European Agenda on Security. It is estimated that EU citizens spend over EUR 24 billion 
every year on illicit drugs
8
. The human and social costs of drugs addiction are very high and it 
generates costs for public health (drug prevention, healthcare and treatment), public safety, 
the environment and labour productivity
9
. 
As regards drug demand, the use of illicit drugs remains one of the most longstanding threats 
to our societies and, whether directly or indirectly, affects the lives of millions of people. At 
least 83.2 million Europeans have reported that they have used cannabis at least once in their 
lifetime, while 17.1 and 12 million respectively have tried cocaine and amphetamines. In 
addition, 1.3 million adults are high-risk opioid users. The prevalence of recorded high-risk 
opioid use has stabilised and in some countries diminished; the prevalence of infectious 
diseases has been decreasing, overall, since 2013. It is estimated that at least 6 800 people 
died from overdoses in the EU in 2014
10
. Drug use is largely concentrated among young 
people (15 to 34 years old); an estimated 17.8 million young adults have used drugs in the last 
year. There appears to have been an increase in drug-related deaths since 2013 and no 
recorded decrease in the use of drugs.
11
  
As regards drug supply, in the past four years, new psychoactive substances (NPSs) have been 
increasingly available on the open market and/or online, posing serious health threats. In 
2015, a total of 98 NPSs were detected, bringing the number of new substances monitored to 
more than 560, of which 70 % have been detected in the last five years. Recorded seizures of 
illicit drugs did not changed substantially in 2013 and 2014 compared with the previous year, 
but a greater total volume of drugs was seized.  
As regards coordination, the mechanisms at EU level, most of which pre-date the current 
Strategy, are effective. Its most prominent coordination body, the EU Council's Horizontal 
Drugs Group (HDG), is considered effective in monitoring the implementation of the Action 
Plan and facilitating dialogue on the state of the drugs phenomenon in Europe. There is 
evidence of consistency over time and continuity across presidencies. In addition, all Member 
States reported that civil society organisations were involved in the development, monitoring 
and/or evaluation of their national drugs policy. 
As regards international cooperation, drug-related priorities have been incorporated into the 
EU’s external policies, strategies and actions targeting third countries and regions. In addition, 
the past years have been an improvement in EU cooperation in order to speak as one voice in 
international fora.  
Finally, regarding information, research, monitoring and evaluation over the last five years the 
EU has provided support to several research projects under a variety of funding mechanisms
12
 
spanning various aspects of the drug issue and related disciplines. Sustained efforts are 
needed to translate the priorities of the Strategy and Action Plan in research. The existence 
and operation of the Early Warning System for new psychoactive substances within the 
                                                            
8  EU Drug Markets Report 2016, Europol and EMCDDA. 
9  European Drug Report 2016, EMCDDA. 
10  This represents an increase on the 2013 figure. 
11  The source for all data in the paragraph is the European Drug Report 2016, EMCDDA. 
12  Including FP7, Horizon 2020 and Health Programme 2014-2020 
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European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is a reflection of 
improved sharing of forensic and toxicological data at EU level over the past years. This early 
warning activity allows the EU to make informed and swift decisions on harmful substances.  
III. Findings of the mid-term assessment of the Strategy  and the final evaluation of 
the 2013-2016 Action Plan  
The evaluation covered the period 2013-2016 and all 28 Member States. It addressed both the 
internal and the external dimensions of the Strategy and the Action Plan. It was based on an 
extensive review of relevant EU and Member State data and documents relating to drug 
markets, trends and drugs strategies
13
. The findings of the evaluation addressed both the mid-
term assessment of the EU Drugs Strategy 2013-2020 and the final evaluation of the EU 
Action Plan on Drugs 2013-2016. 
Some of the main challenges of the evaluation were the fact that the data collected from all 
Member States to feed into it were not always comparable, as well as a lack of baseline 
measures and up to date statistics for certain areas
14
. This makes the attribution and 
assessment of possible trends and developments to the Strategy and the Action Plan difficult, 
which has had an impact on the analysis of the effectiveness of the Strategy and Action Plan 
in terms of quantifying the effects and crediting changes corresponding to the objectives 
solely to the Strategy and Action Plan. However, several research methods
15
 have been used 
for the evaluation and the findings from each data source have been combined, which 
contributed to the weight of evidence. 
The evaluation concluded that the Strategy and Action Plan are still fit for purpose in terms of 
meeting the requirements of drugs policy at EU, national and international levels. All areas 
they tackle remain relevant for addressing all aspects of the drugs phenomenon.   
The evaluation applied the five standard criteria: effectiveness, efficiency, coherence, 
relevance and EU added value. 
A. Effectiveness  
As a first step to assess effectiveness, the evaluation assessed the degree of implementation of 
all the 54 actions of the Action Plan, as well as their impact. The graph below shows the 
progress made in the Action Plan for each of the five pillars: 
                                                            
13  This involved over 90 interviews with representatives from all EU Member States, European 
institutions, agencies, third countries, and other stakeholders; an online survey of European External 
Action Service (EEAS), representatives in non-EU countries; an online public consultation and 
roundtable discussion with representatives from the Civil Society Forum on Drugs. 
14  This is due to the fact that not all Member States provide data on all measures, to the fact that different 
indicators cover different time periods, that some indicators are based on registers or surveys and are 
quantifiable while others rely on expert opinions or qualitative assessments. 
15  Interviews, surveys, desk research, public consultation, roundtable discussions. 
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The evaluation found that implementation of the EU Drugs Strategy and Action Plan has been 
effective, to different degrees, in all five pillars.  
The majority of the actions have been implemented - 53% of actions are completed or on 
track, whilst for 47% of actions some progress has been made but implementation is behind 
plan - and considerable progress has been made on the 15 specific objectives of the Action 
Plan. 
In the area of drug demand reduction, delays relate to the objectives on preventing drug use 
and delaying the onset of drug use and on enhancing the effectiveness of drug treatment and 
rehabilitation. The objective of embed coordinated, best practice and quality approaches in 
drug demand reduction is on track.  
In the area of drug supply reduction, the objectives to enhance effective law enforcement 
coordination and cooperation and enhancing effective judicial cooperation and legislation are 
behind schedule, whilst that related to responding effectively to current and emerging trends 
in illicit drug activity was assessed as on target. 
In the area of coordination, the objectives relating to ensuring effective coordination at EU 
and national-level of drug-related policies and ensuring the participation of civil society in the 
formulation of drugs policy were assessed as on target. 
In the field of international relations, the objective of integrating the Strategy into the EU's 
overall foreign policy framework was assessed as lagging behind, whilst objectives are on 
track relating to improving the cohesiveness of the EU’s approach and visibility in the United 
Nations (UN) and of supporting the process for acceding, candidate and potential candidates 
countries’ to adapt to and align with the EU acquis on drugs. 
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In the field of information, research, monitoring and evaluation, further progress is needed to 
ensure adequate investment in research, data collection, monitoring, evaluation and 
information exchange and to enhance the dissemination of monitoring, research and 
evaluation results at EU and national level. Progress on maintaining networking and 
cooperation and developing capacity within and across the EU’s knowledge infrastructure for 
information, research, monitoring and evaluation of drugs, particularly on illicit drugs was 
good. 
B. Efficiency  
In the absence of a comprehensive, up-to-date overview of drug-related expenditure, the 
evaluation provided indications of the extent to which sufficient financial resources had been 
allocated at EU and Member State level. 
The evaluation could not conclude on the efficiency of the intervention as harmonised 
quantitative data are not available as regards expenditure and related benefits of relevant 
actions across EU Member States. However, the Drugs Strategy and Action Plan managed to 
establish a common EU-wide framework as explained in the "EU added value" section below.  
In the absence of a comprehensive and up-to-date overview of drug-related expenditure, the 
evaluation focussed instead on the extent to which the allocation of financial resources at EU 
and Member State level was perceived as sufficient. Overall, resources were considered by 
stakeholders to be sufficient for the EU Strategy and Action Plan, in particular with regard to 
drug demand and supply. 
C. Coherence 
The priorities and actions in the Strategy and Action Plan were found to be coherent with 
most other relevant EU policies and strategies, such as the European Agenda on Security and 
the European Development Consensus
16
, while more synergies with the EU Health Strategy
17
 
are called for. For example, the evaluation points to the fact that the challenges posed by the 
ageing of the population in Europe or the potential impact of new technologies in the 
prevention area as identified in the EU Health Strategy are not reflected.  
D. Relevance 
According to the evaluation, stakeholders considered the Strategy and Action Plan to be as 
relevant as at the time of their adoption. The five pillar structure continues to address most 
current drugs policy requirements at EU and national level.  All areas tackled in the Strategy 
and Action Plan 2013-2016 remain relevant for addressing all aspects of the drugs 
phenomenon.   
                                                            
16  Joint statement by the Council and the representatives of the governments of the Member States 
meeting within the Council, the European Parliament and the Commission on European Union 
Development Policy: ‘The European Consensus’ OJ C/46/1 of 24.02.2006 
17  COM (2007) 630 final and objectives identified in 2007 will remain valid for the next decade in the 
context of Europe 2020. In addition the Third Health Programme 2014-2020 points to similar 
challenges 
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E. EU added value 
The Strategy and the Action Plan provided added value to individual Member States’ (and 
non-state actors) strategies by establishing a common EU-wide framework and 
institutionalising a process of consensus-building on drugs policy.  
None of them imposes legal obligations on EU Member States, but the evaluation found that 
they have been successful in broadly directing collective action in the field of drugs, both 
within the EU and at international level, and promoting a shared model with a culture of 
defining priorities, objectives, actions and indicators for measuring performance. 
The evaluation also found that the EU added value appears more pronounced in terms of 
demand reduction activities and emerging challenges.  In international development 
cooperation Member States recognised the added value of collectively setting a common 
strategic framework for actions at the EU level. 
The EU now has more of a ‘voice’ in international fora and international relations. This 
provides an important source of guidance for candidate countries, and a framework for 
bilateral cooperation with non-EU countries.  
F. Conclusion 
Overall, the evaluation confirmed that all stakeholders would broadly welcome a new Action 
Plan for 2017-2020. They considered it necessary to continue setting out precise priorities and 
actions relating to each objective, to assign responsibility and to formulate specific, 
measurable indicators.  The comprehensive nature of the Strategy enables stakeholders to 
refine the focus of the priorities over its lifespan while maintaining a reasonable degree of 
coherence. In addition, stakeholders favoured updating the 2013-2016 Action Plan in response 
to new developments and emerging issues.  
The evaluation found that some actions needed to be strengthened or added in order to keep 
up with developing issues and create more synergies with other EU policy areas such as the 
EU Health Strategy.  It also points to the need for a greater level of focus on the use of new 
communication technologies in illicit drug production and trafficking and the role of internet 
in drug prevention. The evaluation shows that the omission of a discussion on recent trends in 
cannabis policy was noted by a wide range of stakeholders and represented one of the most 
frequent items raised when exploring whether there are any issues not covered by the 
Strategy.  
The evaluation also indicates that there is room for improvement in implementation and 
access to risk and harm reduction measures across various Member States and that 
stakeholders from civil society expressed concerns about the extent and quality of these 
measures. 
Finally, the evaluation found that a future Action Plan should continue to include actions to 
monitor NPS, to reduce demand for and supply of them, and to reduce harms associated with 
their use. 
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IV. The draft new Action Plan 2017-2020 - what is new and what has been updated? 
Building on the evaluation findings and recommendations, the Commission is proposing a 
draft EU Action Plan on Drugs 2017-2020, thus covering the remaining years of the existing 
EU Drugs Strategy, in force until 2020. Building on the results of the evaluation, the draft 
Action Plan maintains and strengthens existing actions to address challenges that continue to 
pose a threat to health and security.  It also includes new actions to reflect developments since 
2013 and address emerging challenges not covered previously. Some of the newly introduced 
actions, such as those addressing the use of new technologies for prevention or the 
comprehensive analysis of developments relating to cannabis policy models, are based on the 
evaluation’s findings. Others result from reflections emerging from sources such as the EU 
Drugs Market Report, policy developments at EU level notably in the context of the European 
Agenda on Security and contributions from the civil society. Such actions include:  
 gathering evidence of potential connections between drug trafficking and  
 the financing of terrorist groups and activities;  
 migrant smuggling; and  
 trafficking in human beings 
 the explicit inclusion of vulnerable groups in the drug demand actions  
The new actions and updates as they relate to the five pillars of the Strategy are summarised 
below. 
A. Drug demand reduction 
 
 Stronger synergies will be created between the new Action Plan and the EU Health 
Strategy, particularly as regards the use of information and communications 
technologies (ICT) for prevention purposes. The use of ICT is key to raising awareness, 
especially among children and young people, of the risks and consequences of illicit drugs 
use.
18
 
 Account is taken of the recent work of the Horizontal Drugs Group (HDG) on the misuse 
of prescribed opioids and other psychoactive medicines
19
.  
 In the light of population ageing in the EU there is a need to address the emerging 
challenge of ageing drug users, as also outlined in the EU Health Strategy
20
.   
 Drug use in vulnerable communities will be addressed by refining the targeted measures 
in the Action Plan 2013-2016
21
.  
 Stronger focus on risk and harm reduction measures, aimed at minimising the adverse 
health and social consequences of drug abuse, play a central role in effective drugs policy, 
including in prison settings
22
. 
                                                            
18  A new action 3 was introduced and action 4 has been updated. 
19  Action 5 has been updated: it now refers to the 'misuse of psychoactive medicines'; this includes any 
type of psychoactive/addictive substances used for treatment, all drugs acting on the central nervous 
system and opioids and medicines used in opioid substitution treatment. 
20  Actions 6 and 7 have been updated  
21  Objective 2, several actions under the drug demand reduction pillar and action 48 have been amended to 
reflect this development. In this context, it is suggested that synergies be explored with the European 
Solidarity Corps. 
22  Actions 8 and 9 have been strengthened to reflect the central objective of the EU's positions for 
UNGASS. 
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 Implementation and monitoring of the 2015 Council conclusions23 on minimum quality 
standards in drug demand reduction in the EU
24
.  
 
B. Drug supply reduction 
 
 Stronger focus on judicial cooperation in drugs related cases at EU level is required. To 
get a fuller picture of the impact of supply reduction efforts, Europol, Eurojust and the 
EMCDDA should maintain their work to collect indicators and complement data 
collection, where possible, with qualitative and contextual information
25
. 
 There should be a focus on the continued implementation of the key indicators adopted by 
the 2013 Council conclusions on improving the monitoring of drug supply in the EU
26
. 
Seven indicators have been developed along with a roadmap for their implementation. 
Full data collection for most of them is ongoing or will start in 2017
27
.  
 The New Psychoactive Substances (NPS) legislative package should be rapidly adopted 
and swiftly implemented; monitoring the effects of the new legislative measures will also 
be required in the next years
28
. 
 Implementation29 of the EU legislation on drug precursors which was strengthened in 
2013 with the adoption of significant amendments to the two Regulations
30
.  
 More attention should be given to alternatives sanctions for drug-using offenders. All 
Member States have at least one available and most have more than one
31
. The most 
commonly available sanctions are drug treatment and suspended sentences with a 
treatment option
32
.  
 Greater focus on the use of ICT in illicit drug production and trafficking33as 
established at the June 2016 expert meeting organised by the Commission 
34
 in the context 
of the EU Internet Forum. 
 
C. Coordination 
 
 Greater coherence and coordination with the other Council working groups would help 
the HDG fulfil its role of monitoring the implementation of the Strategy and ensure 
coherence between demand and supply reduction activities and detect relevant synergies
35
.  
                                                            
23  Council conclusions on the implementation of the EU Action Plan on Drugs 2013-2016 regarding 
minimum quality standards in drug demand reduction in the European Union 11985/15 
24  Action 10 has been updated 
25  Action 11 has been updated 
26  Council conclusions on improving the monitoring of drug supply in the European Union 15 November 
2013  
27  Action 17 has been updated 
28  Action 19 has been updated 
29  Action 20 has been amended accordingly 
30  Regulation (EC) No 273/2004 of the European Parliament and of the Council on drug precursors (OJ L 
47, 18.2.2004, p. 1–10) and Council Regulation (EC) No 111/2005 laying down rules for the 
monitoring of trade between the Union and third countries in drug precursors (OJ L 22, 26.01.2005, p. 
1-10) 
31  Study on alternatives to coercive sanctions as response to drug law offences and drug-related crimes, 
May 2016, for the European Commission  
32  Action 22 has been updated 
33  Action 23 has been updated. The challenges are driven by factors such as secure encryption, web 
hosting, the move from surface to deep websites and/or the darknet; the emergence of new forms of 
payment (such as bitcoins); and the growth in drug advertising and exchanges on social media. 
Particular attention has been given to the use of the web for the sale of prescription drugs and NPSs. 
34  Report from "Internet and drugs" expert meeting June 2016 
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 More attention and time should be devoted to discussing the implementation of the 
Action Plan during HDG meetings
36
.  
 As advocated by the EU in global fora, further opportunities should be sought to 
increase civil society's participation in the formulation, implementation, monitoring and 
evaluation of drugs policies at EU and national level
37
.  
 
D. International cooperation 
 
 The evaluation found that there is scope for improving the capacity of EU delegations to 
engage in drugs issues and network with each other on regional basis.
38
 
 Greater focus should be placed on combating illegal drug crop cultivation and on 
enhancing alternative development
39
. 
 In order to address adequately concerns as regards drug-related extrajudicial killings and 
the use of the death penalty, the EU should explore ways of engaging with other 
countries whenever serious drug-related issues arise
40
. 
 Account is also taken of recent developments in the Dublin Group41, which is looking at 
ways of modernising its working methods
42
. 
 The relevant actors have not deemed it essential to holding an annual dialogue on EU and 
Member States' drug-related assistance to other countries so that action has been dropped 
from the draft Action Plan
43
. 
 There is wide consensus that one key area in which the Strategy and Action Plan add 
value is enabling the EU to ‘speak with one voice’ in international fora, as demonstrated 
in the run-up to UNGASS 2016. Focus is needed now on the implementation of the 
UNGASS outcome and on the preparation of the 2019 review process of the 2009 
Political Declaration and Action Plan on International Cooperation towards an integrated 
and balanced strategy to counter the world drug problem
44
 
 
                                                                                                                                                                                          
35 Action 24 has been amended in line with the evaluation’s recommendation that the current coordination 
mechanisms between the HDG and the Standing Committee on Operational Cooperation on Internal 
Security (COSI) be reviewed. In addition, actions 24 and 28 (as amended) also address the need to 
improve coordination between the HDG and thematic Council Working Groups of the Council, e.g. 
those on the UN Working Party and Human Rights. This would improve synergies and cooperation on 
international relations, especially in the framework of the 2019 review process of the 2009 UN Political 
Declaration and Action Plan on International Cooperation towards an Integrated and Balanced Strategy 
to Counter the World Drug Problem. 
36  Action 26 has been updated 
37  Action 31 has been updated 
38  Action 34 has been amended to give full support to EU Delegations’ role in monitoring drugs policy 
developments in non-EU countries and reporting back to the Commission and the European External 
Action Service (EEAS). 
39  Former actions 34 and 35 have been merged in action 35 since they addressed similar issues: illegal 
drug crop cultivation and alternative development continue to be of interest.  
40  Action 38 has been updated; in the light of renewed diplomatic relations, Iran has been added to the list 
of countries with which the EU will seek closer cooperation and conduct dialogues on drugs. 
41  The Dublin Group is a flexible, informal consultation and coordination mechanism for global, regional 
and country-specific problems of illicit drugs production, trafficking and demand. It is based on 
consensus and mutual assistance. Its participants are the EU Member States, Australia, Canada, Japan, 
Norway, the United States, the European Commission and the UNODC. 
42  Action 39 has been updated  
43  Former action 40 has been deleted. 
44  Action 41 has been updated.  
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E. Research, information, monitoring and evaluation 
 
 There should be clear indicators to measure the impact of EU funded projects45.  
 Account is taken of work to promote the scientific evaluation of policies and 
interventions at national, EU and international level.
46
 
 To address a lack of  solid evidence47, a new action48 focuses  on documenting  potential 
connections between drug trafficking and: 
 the financing of terrorist groups and activities, including any overlap between 
the established routes for drug production and trafficking areas and conflict zones 
and financing sources of terrorist cells in the EU;  
 migrant smuggling, creating synergies with the EU’s Action Plan to counter 
migrant smuggling
49
; and  
 trafficking in human beings, creating synergies with the 2012–2016 EU Strategy 
towards the Eradication of Trafficking in Human Beings
50
.  
 In the light of the current debate in some Member States and internationally, current 
cannabis policy models around the world and their impact will be analysed in more 
depth
51
.  
 Account is taken of the work to improve the cooperation between the customs laboratories 
and the forensic laboratories networks, and between Commission services in the fight 
against New Psychoactive Substances (NPS)
52
. 
 
V. Conclusions  
The mid-term assessment of the EU Drugs Strategy 2013-2020 and the final evaluation of the 
EU Action Plan on Drugs 2013-2016 have confirmed the continued relevance of the existing 
Strategy while also indicating a consensus among many stakeholders in favour of an updated 
Action Plan for the remaining years of the Strategy's duration.  
Therefore, the Commission is proposing an Action Plan for 2017-2020 that maintains and 
strengthens existing actions to address challenges that continue to pose a threat to health and 
security. It also includes new actions to reflect developments since 2013 and addresses 
emerging challenges not covered previously.  
The final evaluation of the Strategy and the 2017-2020 Action Plan, as required by the 
Strategy itself, will be presented in 2020.  In 2019 an evaluation of the EMCDDA, including 
the Reitox system
53
, will also be carried out, as required by the EMCDDA founding 
                                                            
45  Action 45 has been updated. 
46  Action 46 has been updated. 
47 Idem 8. 
48  New action 47. 
49  COM (2015) 285 final. 
50  COM (2012) 286 final. 
51  Action 48 was updated. Cannabis is the most widely used drug in the EU. Recent years have seen a 
number of developments in some non-EU countries with regard to cannabis law reform, e.g. as de-
penalisation of use, market regulation or legalisation. 
52  Action 52 has been updated. 
53  Reitox is the European information network on drugs and drug addiction. It was created at the same 
time as the EMCDDA and is made up of ‘national focal points’ or ‘national drug observatories’ 
(designated national institutions or agencies responsible for collecting data and reporting on drugs and 
drug addiction.  
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Regulation
54
. As the above evaluations will provide valuable information on the 
implementation of the 2017-2020 EU Action Plan, a mid-term progress review will not be 
necessary.   
The Commission will now enter into a dialogue on its proposed draft EU Action Plan on 
Drugs 2017-2020 with the European Parliament and the Council. 
                                                            
54  Regulation (EC) No 1920/2006 of the European Parliament and of the Council of 12 December 2006 on 
the European Monitoring Centre for Drugs and Drug Addiction (recast) 
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ANNEX
55
 
1. DRUG DEMAND REDUCTION 
Contribute to a measurable reduction in the use of illicit drugs, in problem drug use, in drug dependence and in drug-related health and social harms as 
well as contributing to a delay in the onset of drug use 
Objective Action Timetable Responsible 
party 
Indicator(s) Data 
collection/ 
assessment 
mechanisms 
1. Prevent drug 
use and, 
secondly, 
delay the onset 
of drug use 
1. Improve the availability and 
effectiveness of evidence-
based
56
 prevention measures that 
take account of: 
a. population risk factors such 
as age; gender; cultural and 
social factors;  
b. situational risk factors such 
as homelessness; migration 
and asylum seeking, drug 
use in nightlife and 
recreational settings; the 
workplace; and driving under 
the influence of drugs; and 
c. individual risk factors such as 
mental health; problem 
behaviour and psychosocial 
development; and other 
factors known to affect 
individual vulnerability to 
drug use such as genetic 
Ongoing MS 
 
 Overarching indicators 1, 11, 12 
 Level of provision at MS level of 
evidence-based universal and 
environmental prevention measures  
 Level of provision at MS level of 
evidence-based targeted prevention 
measures, including family and 
community based measures 
 Level of provision at MS level of 
evidence-based indicated prevention 
measures 
 
 
EMCDDA 
Reporting 
 
 
Reitox 
National 
Reports 
 
MS reporting 
on results of 
measures 
 
                                                            
55
  The draft Action Plan includes in bold newly added parts and in strikethrough the parts that the Commission proposes to remove 
56
  Evidence based should be read in this context as "based on available scientific evidence and experience" 
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Objective Action Timetable Responsible 
party 
Indicator(s) Data 
collection/ 
assessment 
mechanisms 
influences and family 
circumstances  
2. In addition to the prevention of 
drug use, strengthen and better 
target prevention and 
diversionary measures to delay 
the age of first use of illicit drugs 
Ongoing  MS  Overarching indicators 1, 5, 12 
 Level of provision at MS level of 
evidence based prevention and 
diversionary measures that target 
young people in family, community, 
and formal/non-formal education 
settings 
EMCDDA 
Reporting 
 
MS reporting 
on results of 
measures 
3. Exchange of best practices in 
targeting children and young 
people in prevention actions, 
including: 
 
a. programmes and 
campaigns  in formal and 
non/formal education 
settings; 
b. online programmes and 
campaigns; 
c. cooperation with internet 
companies for prevention 
purposes; and 
d. ways of harnessing social 
media to better understand 
drug use and improve 
demand reduction 
Ongoing MS 
 
Civil society 
 
EMCDDA 
 Type of exchanges of best practices 
between MS 
 Positive evaluations of behavioural 
outcomes of best practice 
interventions (where available) 
EMCDDA 
best 
practices 
portal 
 
MS 
reporting 
 
Civil society 
reporting 
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Objective Action Timetable Responsible 
party 
Indicator(s) Data 
collection/ 
assessment 
mechanisms 
responses 
4. Raise awareness of the risks and 
consequences associated with the 
use of illicit drugs and other 
psychoactive substances, 
including by cooperating with 
internet companies and 
prevention experts to target 
children and young people 
better 
Ongoing MS 
COM 
EMCDDA 
 
 Overarching indicators 5, 12 
 
 Level of awareness in general and 
youth populations of healthy lifestyles 
and of the risks and consequences of 
the use of illicit drugs and other 
psychoactive substances  
 
EMCDDA 
Reporting 
 
Eurobaro-
meter surveys 
 
ESPAD 
 
HBSC 
 5. Enable a more informed response 
to the challenge of the misuse of  
prescribed and ‘over the counter’ 
opioids and other psychoactive 
medicines  
 
 
2017-2020 MS 
Council WP 
(HDG) 
EMA 
EMCDDA 
 
 Collation of data by MS on levels and 
patterns of prescribing of psychoactive 
medicines by 
end 2014 
 Number of initiatives that focus on the 
promotion of appropriate use of 
prescribed and ‘over the counter’ 
opioids and other psychoactive 
medicines  
 Collation of evidence and 
international examples on how to 
reduce the risks of diversion and 
abuse of psychoactive medicines 
MS 
Reporting 
 
EMCDDA 
 
Report of 
Alice RAP 
project 
 16 
 
Objective Action Timetable Responsible 
party 
Indicator(s) Data 
collection/ 
assessment 
mechanisms 
 Training of medical practitioners 
and other health professionals in the 
use of medication to control pain and 
treat suffering  
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Objective Action Timetable Responsible 
party 
Indicator(s) Data 
collection/ 
assessment 
mechanisms 
2. Enhance the 
effectiveness of 
drug treatment 
and 
rehabilitation, 
including 
services for 
people with co-
morbidity, to 
reduce the use of 
illicit drugs; 
problem drug 
use; the incidence 
of drug 
dependency and 
drug-related 
health and social 
risks and harms 
and to support the 
recovery and 
social 
re/integration of 
problematic and 
dependent drug 
users and of 
vulnerable 
communities, 
including by 
6. Develop and expand the diversity, 
availability, coverage and 
accessibility of evidence-based 
comprehensive and integrated 
treatment services. Ensure that 
these services address polydrug 
use (combined use of illicit 
and/or licit substances including 
alcohol and tobacco) and the 
emerging needs of the ageing 
drug-using population and 
gender-specific issues. Develop 
early intervention/treatment 
and therapy programmes for 
child and adolescent drug 
users. 
 
Ongoing MS  Overarching indicators 1, 6, 11 
 Extent of the diversity of evidence-
based comprehensive and integrated 
treatment services at MS level 
including those which address 
polydrug use and the needs of the 
ageing drug-using population 
 MS data on treatment retention and 
outcomes 
 
EMCDDA 
Reporting   
 
Reitox  
National 
Reports 
 
EMCDDA 
Best Practice 
Portal 
 
EU Drugs 
Strategy and 
Action Plan 
final 
evaluation 
 
MS 
reporting 
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Objective Action Timetable Responsible 
party 
Indicator(s) Data 
collection/ 
assessment 
mechanisms 
building 
synergies with 
the EU 
Solidarity 
Corps.  
7. Expand the provision of   
rehabilitation/recovery services 
with an emphasis on services 
that: 
a. focus on providing a 
continuum of care through 
case management and  
interagency collaboration    
for  individuals; 
b. focus on supporting the social 
re/integration   (including the 
employability and housing) 
of problem and dependent 
drug users including 
prisoners and ageing drug 
users, where relevant;   
c. Strengthen the diagnostic 
process and the treatment of     
psychiatric and physical co-    
morbidity involving drug use, 
for e.g.  with rapid testing 
for hepatitis B and C and 
HIV as well as other 
sexually transmitted 
infections and tuberculosis, 
in line with the minimum 
quality standards on drug 
demand reduction adopted 
by the Council in 2015; 
d. take account of gender-
Ongoing MS  Overarching indicator 11 
 
MS data on: 
 Extent of increase in 
rehabilitation/recovery services 
adopting case management and inter-
agency approaches 
 Extent of increase in the number of 
gender specific 
rehabilitation/recovery 
programmes 
 Extent of increase in the number of 
comprehensive community care 
programmes, specifically targeted at 
drug users with co-morbidity, 
involving partnerships between both 
mental health and drug rehabilitation/ 
recovery services and prisons 
 Level and duration of abstentions 
from consumption of illicit and/or licit 
drugs by people leaving drug 
treatment 
 Availability of treatment options to 
meet needs of people who experience 
relapses to drug use and of ageing 
drug users 
 
 
 
EMCDDA 
Reporting 
 
MS 
Reporting on  
results of 
services  
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Objective Action Timetable Responsible 
party 
Indicator(s) Data 
collection/ 
assessment 
mechanisms 
specific needs; and 
e. reach out to vulnerable 
communities, including 
children and teenagers, 
ethnic minorities, migrants 
and asylum seekers, 
LGBTI, commercial sex 
workers and prisoners, 
people living with 
HIV/AIDS and the 
homeless. 
8. (a) Scale up access to harm 
reduction services e.g. needle 
and syringe exchange 
programmes, opioid 
substitution treatment, take-
home naloxone programmes 
Ensure that treatment and 
outreach services incorporate 
greater access to risk and harm 
reduction options to lessen the 
negative consequences of drug 
use and to substantially reduce 
the number of direct and indirect 
drug-related deaths and 
infectious blood borne diseases 
associated with drug use but not 
limited to HIV and viral hepatitis, 
as well as sexually transmittable 
Ongoing MS 
EMCDDA 
COM 
Civil Society 
Forum on 
Drugs 
Civil Society 
Forum on 
HIV/AIDS, 
Viral 
Hepatitis 
and 
Tuberculosis 
 Overarching indicators 2, 3, 4, 11 
 Extent of increased availability of and 
access to evidence based risk and 
harm reduction measures in MS 
 Type of exchanges of best practices 
on risk and harm reduction 
measures 
 Number of MS reaching the WHO 
recommendation of a minimum 
threshold of 200 sterile needles and 
syringes distributed per injecting 
drug user per year 
 Coverage of opioid substitution 
treatment programmes among 
people with opioid dependence  
 Extent of increased availability of 
take home naloxone programmes 
and nightlife harm reduction 
EMCDDA 
Reporting  
 
Reitox 
National 
Reports 
 
MS 
Reporting on 
services  
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Objective Action Timetable Responsible 
party 
Indicator(s) Data 
collection/ 
assessment 
mechanisms 
diseases and tuberculosis 
 
(b) Identify and overcome 
barriers in access to treatment 
for hepatitis C among people 
who inject drugs, including 
prisoners and other vulnerable 
groups 
 
(c) Exchange best practices on 
risk and harm reduction 
measures e.g. needle and 
syringe exchange programmes, 
opioid substitution treatment, 
drug consumption rooms, take-
home naloxone programmes, 
peer based interventions, 
outreach treatment 
programmes, hepatitis C 
treatment, pill testing, self-
testing for HIV/AIDS, etc. 
 
 programmes 
 Number of programmes facilitating 
the access of people who inject 
drugs into treatment for the 
hepatitis C virus (HCV) and people 
covered 
 Number of harm reduction 
programmes targeting vulnerable 
communities e.g. ethnic minorities, 
migrants and asylum seekers, 
LGBTI,  commercial sex workers 
and prisoners 
 Degree of implementation of 
ECDC/EMCDDA guidance on 
prevention and control of infectious 
diseases among people injecting 
drugs 
 Degree of implementation of EU 
minimum quality standard in drug 
demand reduction III (Treatment 
services provide voluntary testing for 
blood-borne infectious diseases, 
counselling against risky behaviours 
and assistance to manage illness) 
 
 
9. Scale up the development, 
availability and coverage of 
health care measures for drug 
users in prison and after release 
with the aim of achieving a 
quality of care equivalent to that 
Ongoing MS  Overarching indicator 10 
 Availability of services for drug users 
in prisons (including opioid 
substitution treatment and needle 
and syringe exchange programmes) 
and the extent to which prison health 
EMCDDA 
Reporting 
 
Reitox 
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Objective Action Timetable Responsible 
party 
Indicator(s) Data 
collection/ 
assessment 
mechanisms 
provided in the community care policies and practices incorporate 
care models comprising best practices 
in needs assessment and continuity of 
care for prisoners during 
imprisonment 
 Extent of decrease in drug-related 
physical and mental health problems 
amongst prisoners 
 Extent to which prison based services 
and community based services 
provide continuity of care for 
prisoners upon release with particular 
emphasis on avoiding drug overdoses 
National 
Reports 
 
 
MS 
Reporting on 
services  
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Objective Action Timetable Responsible 
party 
Indicator(s) Data 
collection/ 
assessment 
mechanisms 
3. Embed co-
ordinated, best 
practice and 
quality 
approaches in 
drug demand 
reduction  
10. Implement the EU minimum 
quality standards adopted by the 
Council in 2015
57
 that help 
bridge the gap between science 
and practice, for:  
a. environmental, universal, 
selective and indicated 
prevention measures; 
b. early detection and 
intervention measures;  
c. risk and harm reduction 
measures; and  
d. treatment, rehabilitation, 
social integration and 
recovery measures 
and monitor their implementation.  
2017-2020 Council  
Council WP 
(HDG) 
MS 
COM 
EMCDDA 
 Consensus achieved by MS on 
minimum quality standards building 
on previous EU preparatory studies 
 Evidence review of drug demand 
reduction programmes 
implemented in accordance with the 
standards;   
 Number of specialist training 
programmes available for 
practitioners in drug demand 
reduction and/or estimated number 
of practitioners reached by 
specialist training programmes; 
 Involvement of civil society in the 
implementation of the standards, 
including in planning and 
introduction 
 Number and impact of projects and 
programmes supported at EU level 
that promote the exchange of  best 
practices in the implementation of 
these standards 
 Engagement in inter-ministerial 
cooperation to support 
implementation of these standards. 
 
EMCDDA 
Best Practice 
Portal 
 
COM 
Biennial 
Progress 
Report 
 
MS 
reporting 
 
EU Drugs 
Strategy and 
Action Plan 
final 
evaluation 
                                                            
57  Council conclusions on the implementation of the EU Action Plan on Drugs 2013-2016 regarding minimum quality standards in drug demand reduction in the European 
Union 11985/15 
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2. DRUG SUPPLY REDUCTION 
Contribute to a measurable reduction of the availability and supply of illicit drugs in the EU 
Objective Action Timetable Responsible 
party 
Indicator(s) Data collection/ 
assessment 
mechanisms  
4. Enhance effective 
law enforcement co-
ordination and co-
operation within the 
EU to counter illicit 
drug activity, in 
coherence, as 
appropriate, with 
relevant actions 
determined through 
the EU policy cycle  
11. Utilise to best effect available 
intelligence and information 
sharing law enforcement 
instruments, channels and 
communication tools used to 
collate and analyse drug-related 
information  
 
Ongoing MS 
Europol 
Eurojust 
Council WP 
(COSI) 
 
 Overarching indicator 7 
 Extent of high impact 
intelligence led and targeted 
activities, of joint operations, 
joint investigation teams and 
cross border cooperation 
initiatives focusing on 
criminal organisations 
engaged in illicit drug activity 
 Increased use of Europol’s 
drug-related information-
sharing, analysis and expert 
systems  
 Results achieved from 
EMPACT projects and 
bilateral and multilateral 
initiatives 
 Number of drug-related 
cases referred to Eurojust 
and Europol, including 
qualitative, contextual 
information about the cases 
 
EMCDDA 
Reporting 
 
EU Agencies 
Europol Reporting  
 
Eurojust 
Reporting 
 
EMPACT Driver 
Reports 
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Objective Action Timetable Responsible 
party 
Indicator(s) Data collection/ 
assessment 
mechanisms  
12. Identify and prioritise the most 
pressing threats associated with 
drug-related organised crime 
 
2017 Council  
Council WP 
(COSI) 
Europol 
MS 
COM 
 
 EU Policy Cycle and Crime 
priorities for 2017-2021 in 
place 
 
Council 
Conclusions on EU 
Policy Cycle 
 
EU SOCTA 
 
Multi-annual 
Strategic Plans 
(MASPs) 
 
EMPACT 
Evaluation 
EMPACT Driver 
Reports 
 
Europol Directors' 
Report 
13. Strengthen CEPOL’s training for 
law enforcement officers in 
relation to illicit drug production, 
trafficking and financial crime, 
particularly training methods and 
2017-2020  MS 
CEPOL 
 Training needs assessment 
carried out regularly 
 Availability and uptake of 
relevant training courses  
 Number of law enforcement 
COM Biennial 
Progress  
Report 
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Objective Action Timetable Responsible 
party 
Indicator(s) Data collection/ 
assessment 
mechanisms  
techniques  
a. to combat the use of new 
communication technologies 
in illicit drug production and 
trafficking;  
b. to enhance asset confiscation; 
c. to combat money laundering;  
d. to detect and dismantle illicit 
clandestine laboratories and 
cannabis cultivation sites.  
Europol 
Council WP 
(COSI) 
COM 
officers trained and effectively 
deployed as a result 
 
CEPOL Annual 
Report  
 
CEPOL Curricula  
 
EMPACT 
Evaluation  
EMPACT Driver 
Reports 
 14. Improve counter narcotic 
activities through strengthening 
and monitoring the effectiveness 
of regional information-sharing 
platforms and regional security-
sharing platforms with the aim of 
disrupting and suppressing 
emerging threats from changing 
drug trafficking routes 
Ongoing COM 
MS 
Europol 
 
Council WP 
(COSI) 
 
Regional 
 Overarching indicator 7 
 Number of intelligence led 
activities leading to the 
disruption and suppression of 
drug trafficking routes  
 Level of information sharing 
through effective activity of the 
liaison officer network 
 
EMCDDA 
Reporting 
 
Security/ 
Information -
sharing Platforms 
and Evaluation 
Reports 
 
EU SOCTA  
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Objective Action Timetable Responsible 
party 
Indicator(s) Data collection/ 
assessment 
mechanisms  
Information- 
Sharing 
Platforms 
 
Regional 
Security-
Sharing 
Platforms 
 
 
EMPACT 
Evaluation  
EMPACT Driver 
Reports 
 
Europol Directors' 
Report 
 
MAOC(N)
58
 
15. Strengthen actions to prevent the 
diversion of drug precursors and 
pre-precursors for use in the illicit 
manufacture of drugs 
Ongoing MS 
Europol 
COM 
Council WP 
(CUG 
COSI) 
 
 Number of cases and quantity 
of stopped or seized 
shipments of precursors 
intended for illicit use 
 Results achieved from 
EMPACT projects 
 Use of Pre-Export 
Notification (PEN) Online 
System and increased use of 
the Precursors Incident 
Communication System 
(PICS) 
Reports from EU 
and MS Law 
Enforcement 
Agencies 
 
EMPACT 
Evaluation  
EMPACT 
                                                            
58
  The Maritime Analysis and Operations Centre – Narcotics (MAOC (N), based in Lisbon, is an initiative by 7 EU Member Countries: France, Ireland, Italy, Spain, 
Netherlands, Portugal and the UK and is co-funded by the Internal Security Fund of the European Union. The Centre provides a forum for multi-lateral 
cooperation to suppress illicit drug trafficking by sea and air. 
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Objective Action Timetable Responsible 
party 
Indicator(s) Data collection/ 
assessment 
mechanisms  
 Number of joint follow up 
meetings and other activities 
linked to the prevention of the 
diversion of precursors and 
pre-precursors 
 
Driver Reports 
 
Europol Directors' 
Report 
16. Counter cross-border drug 
trafficking, including through 
container and parcel shipments, 
and improve border security 
notably at EU seaports, airports 
and land border crossing points 
through intensified efforts, 
including information and 
intelligence sharing, by relevant 
law enforcement agencies  
 
 
Ongoing MS 
Europol 
Council WG 
(CCWP 
COSI) 
 
 Increased number of multi-
disciplinary/multi-agency joint 
operations and cross border 
cooperation initiatives  
 Number of effective 
Memoranda of Understanding 
(MOU) agreed between law 
enforcement agencies and 
relevant bodies such as airlines, 
air express couriers, shipping 
companies, harbour authorities 
and chemical companies 
 Results achieved from 
EMPACT projects 
 Improved intelligence and 
information sharing on cross-
border drug trafficking 
utilising, inter alia, available 
border surveillance systems 
airports and land border crossing 
points 
COM Biennial 
Progress  
Report 
 
EMPACT 
Evaluation Driver 
Reports 
 
Europol Directors' 
Report 
 
Europol reporting 
 
MS Reporting 
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Objective Action Timetable Responsible 
party 
Indicator(s) Data collection/ 
assessment 
mechanisms  
17. Implement the key indicators on 
drug supply reduction adopted 
by the Council in 2013
59
 
2017-2020 
 
COM 
MS 
Council 
Council WP 
(HDG) 
EMCDDA 
Europol 
 
 Roadmap developed and 
agreed on the implementation 
of key drug supply indicators 
MS agreement reached on key 
drug supply indicators  
 number and quantity of drug 
seizures 
 purity and content of drugs 
 drug prices 
 drug production facilities 
dismantled 
 drug law offences 
 drug availability in 
population surveys 
 market size estimates  
Overview of 
existing supply data 
collection in MS 
 
EMCDDA 
Reporting 
 
Europol reporting 
 
COM Biennial 
Progress Report 
5. Enhance effective 
judicial co-operation 
and legislation 
within the EU 
18. Strengthen EU judicial co-
operation in targeting cross-border 
drug trafficking, money 
laundering, and in the confiscation 
of the proceeds of drug-related 
2017-2020 
 
Council 
COM 
 Adoption and Timely 
implementation of agreed EU 
measures and legislation on                      
(a) confiscation and recovery 
of criminal assets
60
; (b) 
Eurojust Reporting 
 
                                                            
59  Council conclusions on improving the monitoring of drug supply in the European Union 15 November 2013  
60
  Directive 2014/42/EU of the European Parliament and of the Council on the freezing and confiscation of instrumentalities and proceeds of crime in the European 
Union; Council Decision 2007/845/JHA concerning cooperation between Asset Recovery Offices of the member States in the field of tracing and identification of 
proceeds of, or other property related to, crime; Council  Framework Decision 2006/783/JHA on the application of the principle of mutual recognition to 
confiscation orders. Council Framework Decision 2003/577/JHA on the execution in the European Union of orders freezing property or evidence, Commission 
proposal for a Regulation of the European Parliament and of the Council on the mutual recognition of freezing and confiscation orders COM(2016) 819; Council 
Framework Decision 2005/212/JHA on confiscation of crime-related proceeds, instrumentalities and property; Council Framework Decision 2003/577/JHA on the 
execution in the European Union of orders freezing property or evidence.  
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Objective Action Timetable Responsible 
party 
Indicator(s) Data collection/ 
assessment 
mechanisms  
organised crime 
 
MS 
Eurojust 
 
money laundering
61
; (c) 
approximation of drug 
trafficking offences and 
sanctions across the EU
62
 
 Increased number of financial 
investigations and 
confiscations in relation to the 
proceeds of drug-related 
organised crime through EU 
judicial cooperation 
 Timely and effective 
responses to mutual assistance 
requests and European Arrest 
Warrants in relation to illicit 
drug trafficking  
MS reporting 
 
 
COM Biennial 
Progress Report  
 
 
19.  Adopt and implement new EU 
legislative measures to address the 
emergence, use and rapid spread 
of new psychoactive substances 
 
2017-2020 COM 
Council 
Council WP 
(HDG) 
 EU legislation in place  
 Implementation of EU 
legislation in MS  
 Development of EU 
guidelines for the 
information exchange and 
risk assessment procedures 
COM Biennial 
Progress Report  
MS reporting 
                                                            
61
  Directive (EU) 2015/849 of the European Parliament and of the Council on the prevention of the use of the financial system for the purposes of money laundering 
or terrorist financing, amending Regulation (EU) No 648/2012 of the European Parliament and of the Council, and repealing Directive 2005/60/EC of the 
European Parliament and of the Council and Commission Directive 2006/70/EC; Council Framework Decision 2001/500/JHA on money laundering, the 
identification, tracing, seizing and confiscation of instrumentalities and the proceeds of crime. Commission proposal for a Directive of the European Parliament 
and of the Council on countering money laundering by criminal law COM (2016) 826.Regulation (EU) 2015/847 of the European Parliament and of the Council on 
information accompanying transfers of funds and repealing Regulation (EC) No 1781/2006; Regulation (EC) No 1889/2005 of the European Parliament and of the 
Council on controls of cash entering or leaving the Community. Commission proposal for a Regulation of the European Parliament and of the Council  on 
controls on cash entering or leaving the Union and repealing Regulation (EC) No 1889/2005 
62
  Council Framework Decision 2004/757/JHA of 25 October 2004 laying down minimum provisions on the constituent elements of criminal acts and penalties in the 
field of illicit drug trafficking, as regards the definition of drug 
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Objective Action Timetable Responsible 
party 
Indicator(s) Data collection/ 
assessment 
mechanisms  
MS 
EMCDDA 
Europol 
 Monitor the effects of new 
legislative measures with a 
special focus on the 
replacement-effect in the 
illegal drug market 
 
20.  Implement effectively EU 
legislation on drug precursors to 
prevent their diversion without 
disrupting lawful trade 
Ongoing Council 
COM 
MS 
 Implementation of 
Regulations of the European 
Parliament and of the Council 
on drug precursors amending 
both Council Regulation (EC) 
No. 111/2005 and  Regulation 
(EC) No. 273/2004  
COM Biennial 
Progress Report  
EU Annual Report 
on Drug Precursors 
21.  Combat the use of certain 
pharmacologically active 
substances (as defined in EU 
Directive 2011/62) as cutting 
agents for illicit drugs 
Ongoing MS 
COM 
EMA 
EMCDDA 
Europol 
 Number of seizures of active 
substances used as cutting 
agents for illicit drugs 
 Timely implementation of 
new EU legislative 
requirements aimed at 
securing the supply chain for 
active substances under 
Directive 2011/62/EU, the 
Falsified Medicines Directive 
Reports from the 
CCWP and CUG 
 
MS Reporting 
 22.  Members States to provide and 
apply, where appropriate and in 
accordance with their legal 
frameworks, alternatives to 
coercive sanctions (such as 
education, treatment, 
rehabilitation, aftercare and social 
2017-2020 MS 
Council 
(HDG) 
 Increased availability and 
implementation of alternatives 
to coercive sanctions prison 
for drug-using offenders in the 
areas of education, treatment, 
rehabilitation, aftercare and 
social integration. 
Reitox National 
Reports 
 
MS reporting 
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Objective Action Timetable Responsible 
party 
Indicator(s) Data collection/ 
assessment 
mechanisms  
integration) for drug using 
offenders, including: 
a. Education 
b. (Suspension of sentence 
with) treatment 
c. Suspension of investigation 
or prosecution 
d. Rehabilitation 
e. Aftercare and social 
integration 
and develop the Fundamental 
rights dimension as a key factor 
to better balance repression and 
promote rehabilitation. 
 Increased monitoring, 
implementation and 
evaluation of alternatives to 
coercive sanctions  
 Type and number of 
alternatives to coercive 
sanctions provided for and 
implemented by MS 
 Information on beneficiaries 
of alternative sentences  who 
reoffend within five years 
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Objective Action Timetable Responsible 
party 
Indicator(s) Data collection/ 
assessment 
mechanisms  
6. Respond 
effectively to 
current and 
emerging trends 
in illicit drug 
activity 
23.  Identify strategic responses to 
address the role of new 
communication technologies 
and the hosting of associated 
websites, in the production, 
marketing, purchasing and 
distribution of illicit drugs, 
including controlled new 
psychoactive substances at 
national and EU level, including 
by: 
a. Cooperation with industry  
b. EU and national funding for 
relevant research and 
development of tools to 
support the work of law 
enforcement  
c. Setting up of a glossary of 
terms  
d. Setting up an inventory of 
existing monitoring tools for 
the web and darknet  
e. Providing specialised 
training for law 
enforcement, customs and 
border guards, prosecutors 
and judges 
f. Continuous and proactive 
monitoring of online 
marketplaces by law 
enforcement 
2017-2020 Council 
COM 
Council WP 
(HDG, 
COSI) 
MS 
Europol 
CEPOL 
EMCDDA 
 
 Results achieved from law 
enforcement 
actions targeting drug-related 
crime via the internet  
 Increased number of joint 
operations and    
cross border cooperation 
initiatives 
 Number and impact of 
funded research projects 
and tools developed to 
support law enforcement 
 Number of 
agreements/discussions with 
relevant industry partners 
 Setting up of a glossary of 
terms 
 Setting up of an inventory of 
monitoring tools 
 Numbers of training 
sessions for relevant 
stakeholders 
 Number of meetings with 
international partners in 
which the action was 
discussed 
Progress Interim 
Review of the EU 
Policy Cycle 
Priorities 
 
EMPACT 
Evaluation and  
Driver Reports 
 
Europol Directors' 
Report 
 
CEPOL 
Statistics/Annual 
Report 
 
MS Reporting 
 
Reports from EU 
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Objective Action Timetable Responsible 
party 
Indicator(s) Data collection/ 
assessment 
mechanisms  
g. Exchange of best practices 
with international partners 
h. Streamlining of mutual legal 
assistance proceedings (and 
where applicable, mutual 
recognition), in line with the 
09 June 2016 Council 
Conclusions on improving 
criminal justice in 
cyberspace
63
 
Agencies 
 
COM 
                                                            
63
  Council Conclusions on improving criminal justice in cyberspace 09 June 2016 
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3. CO-ORDINATION 
Member States and EU to effectively co-ordinate drugs policy 
Objective Action Timetable Responsible 
party 
Indicator(s) Data 
collection/ 
assessment 
mechanisms  
7. Ensure 
effective EU co-
ordination in the 
drugs field 
24.  Enhance information sharing 
between the HDG and other relevant 
Council Working Groups and in 
particular COSI to enhance 
coordination as regards the drug 
supply reduction pillar 
 
Enhance information sharing 
between the HDG and other 
relevant geographical and 
thematic Council Working 
Groups including: COAFR, 
COASI, COEST, COLAT, 
COWEB, CONUN and COHOM 
Ongoing PRES 
Council 
EEAS 
Council WP 
(HDG) 
 Extent to which the EU Drugs 
Strategy/and Action Plan are taken 
into account in the Programmes of 
other Council Working Groups  
including COSI, COAFR, COASI, 
COEST, COLAT, COWEB, 
CONUN and COHOM. 
 Regular information point on the 
HDG agenda (once per 
Presidency) on activities linked 
to drug-related priorities of the 
EU Policy Cycle  (based on 
EMPACT reporting) in the 
presence of the COSI Support 
Group chair, if relevant 
Council 
Working 
Group (HDG) 
reporting  
 
Presidency 
reporting 
25.  Each Presidency may convene 
meetings of the National Drugs Co-
ordinators, and of other groupings as 
appropriate, to consider emerging 
trends, effective interventions and 
other policy developments of added 
value to the EU Drugs Strategy and 
to MS  
Biannually PRES 
MS 
 
 Extent to which National Drug Co-
ordinators’ meeting agenda reflects 
developments, trends and new 
insights in policy responses and 
provides for improved 
communication and information 
exchange 
Presidency 
Reporting 
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Objective Action Timetable Responsible 
party 
Indicator(s) Data 
collection/ 
assessment 
mechanisms  
26.  The HDG will facilitate (a) 
monitoring of the implementation of 
the Action Plan through thematic 
debates; and (b)  an annual dialogue 
on the state of the drugs 
phenomenon in Europe 
(a) 
Biannually
Ongoing 
 
(b) 
Annually 
PRES 
Council WP 
(HDG) 
MS 
COM 
EMCDDA 
Europol 
 Extent of implementation of the 
Action Plan 
 Number of actions from the 
Action Plan addressed in 
thematic debates in the HDG  
 Timeliness of dialogue at the HDG 
on latest drug-related trends and 
data 
Presidency 
Reporting 
27.  Ensure consistency and continuity 
of MS and EU actions across 
Presidencies to strengthen the 
integrated, balanced and evidence-
based approach to drugs in the EU  
Biannually
Ongoing 
PRES 
PRES Trio 
MS 
COM 
Council WP 
(HDG) 
EMCDDA 
Europol 
 Extent of consistency and 
continuity of actions across 
Presidencies 
 Advancement in implementation of 
EU Drugs Strategy priorities across 
Presidencies 
 
Presidency 
Reporting 
  
28.  Ensure co-ordination of EU drugs 
policies and responses, to support 
international co-operation between 
the EU, third countries and 
Ongoing EEAS 
COM 
Council WP 
  Level of consistency and 
coherence in the objectives, 
expected results and measures 
foreseen in EU actions on drugs 
  Inclusion of drug-related priorities 
Annual EEAS 
Report to the 
HDG 
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Objective Action Timetable Responsible 
party 
Indicator(s) Data 
collection/ 
assessment 
mechanisms  
international organisations   (HDG) 
MS 
 
in strategies of relevant EU bodies 
  Intensified co-operation between 
the HDG and the 
geographical/regional and 
thematic working groups, 
including COAFR, COASI, 
COEST, COLAT, COWEB, 
CONUN and COHOM 
 
COM 
Biennial 
Progress 
Report 
 29.  Achieve a co-ordinated and 
appropriate level of resources at EU 
level and Member State level to 
fulfil the priorities of the EU Drugs 
Strategy 
Annually MS 
COM 
EEAS 
Council 
Council WP 
(HDG) 
 Overarching indicator 14 
 Amount of funding at EU level, 
and where appropriate, MS level 
  Extent of co-ordination on drugs-
related financial programmes 
across Council Working Groups 
and COM 
EMCDDA 
Reporting 
 
COM 
reporting 
 
COM 
Biennial 
Progress 
Report  
8. Ensure 
effective co-
ordination of 
drug-related 
policy at national 
level  
30.  Co-ordinate actions on drugs policy 
between Government 
Departments/Ministries and relevant 
agencies at MS level and ensure 
appropriate multi-disciplinary 
representation on, or input to, HDG 
Ongoing MS 
 
 Overarching indicator 14 
 
 Effectiveness of a horizontal drug 
policy co-ordination mechanism at 
MS level 
EMCDDA 
Reporting 
 
Reitox 
National 
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Objective Action Timetable Responsible 
party 
Indicator(s) Data 
collection/ 
assessment 
mechanisms  
delegations  Number of cross-cutting actions in 
drug demand and supply reduction 
at Member State level 
 
Reporting 
 
COM 
Biennial 
Progress 
Report  
 
MS Reporting 
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Objective Action Timetable Responsible 
party 
Indicator(s) Data 
collection/ 
assessment 
mechanisms  
9. Ensure the 
participation of 
civil society  in 
drugs policy 
31.  Promote and support strengthen 
dialogue with, and involvement of, 
civil society and the scientific 
community in the formulation, 
implementation, monitoring and 
evaluation development,  of drugs 
policies at MS and EU levels 
Ongoing MS 
COM 
Council WP 
(HDG) 
PRES 
Civil Society 
Forum on 
Drugs 
 
 Timely dialogues between EU 
Civil Society Forum on Drugs and  
the HDG during each Presidency 
period  
 Engagement of EU Civil Society 
Forum in reviewing 
implementation of the EU Drugs 
Action Plan 
 Level of involvement of civil 
society in MS and EU drugs policy 
formulation, development and 
implementation, monitoring and 
evaluation with particular regard 
to the involvement of drug users, 
clients of drug-related services and 
young people 
 Timely dialogue between the 
scientific community (natural and 
social sciences, including 
neuroscience and behavioural 
research) and the HDG 
 Development of a database to 
facilitate communication within  
EU civil society on matters 
relating to  EU and MS drugs 
policies 
 
COM 
Biennial  
Progress 
Report 
 
Feedback  
from EU 
Civil Society 
Forum on 
Drugs and 
from Civil 
Society 
Representativ
es at MS and 
EU level 
 
MS Reporting 
 
Feedback 
from 
Scientific 
Community 
 39 
 
Objective Action Timetable Responsible 
party 
Indicator(s) Data 
collection/ 
assessment 
mechanisms  
through the 
EMCDDA 
Scientific 
Committee 
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4. INTERNATIONAL CO-OPERATION 
Strengthen dialogue and cooperation between the EU and third countries and international organisations on drugs issues in a comprehensive and 
balanced manner  
Objective Action Timetable Responsible 
party 
Indicator(s) Data 
collection/ 
assessment 
mechanisms  
10. Integrate the 
EU Drugs Strategy 
within the EU's 
overall foreign 
policy framework 
as part of a 
comprehensive 
approach that 
makes full use of 
the variety of 
policies and 
diplomatic, 
political and 
financial 
instruments at the 
EU's disposal in a 
coherent and co-
ordinated manner 
32.  Ensure policy coherence between the 
internal and external aspects of the EU 
drugs policies and fully integrate drugs 
issues within the political dialogues and 
framework agreements between the EU 
and its partners and in the EU advocacy 
on global issues or challenges 
Ongoing COM 
EEAS  
PRES  
Council WP 
(HDG) 
MS 
 
 Overarching indicator 13 
 Drug policy priorities 
increasingly reflected in 
EU’s external policies and 
actions 
 Inclusion of drug-related 
priorities in EU strategies 
with third countries and 
regions 
 Number of agreements, 
strategy papers, action plans 
in place 
 
EEAS 
Reporting  
 
Mid-Term 
Review of 
EU Drugs 
Strategy  
 
COM 
Biennial 
Progress 
Report  
33. Ensure that the policy priorities and the 
balance between demand and supply 
reduction are well reflected in policy 
options and in the programming, 
implementation and monitoring of 
external assistance, particularly in source 
and transit countries, through projects 
involving: 
a. development of integrated,  balanced 
Ongoing COM 
MS 
EEAS 
 Extent to which EU’s Drug 
policy priorities, especially 
the balance between 
demand and supply 
reduction, are reflected in 
funded priorities and 
projects 
 Level of implementation of 
co-ordinated actions in 
COM 
Biennial 
Progress 
Report  
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Objective Action Timetable Responsible 
party 
Indicator(s) Data 
collection/ 
assessment 
mechanisms  
and evidence-based drug policies; 
b. supply reduction; 
c. the prevention of the diversion of 
drug precursors and pre-precursors; 
d. drug demand reduction; and  
e. alternative development measures  
 
action plans between the 
EU and third countries and 
regions 
 Number of third country 
national strategies and 
action plans that incorporate 
integrated drug policies 
EEAS 
Reporting on 
Programming 
COM and 
MS 
Programme 
Monitoring 
and 
Evaluation 
Reports 
34.  Improve capacity and strengthen the 
role of EU Delegations to enable them to 
proactively engage on drugs policy 
issues and effectively report back on 
the local situation on drugs 
2017-2020 EEAS 
COM 
MS 
 Relevant expertise, training 
and policy guidance 
provided to EU Delegations 
 Regional networking 
among EU Delegations on 
drug issues enhanced 
 Co-ordination with MS 
enhanced 
EEAS  
COM 
Reporting   
EU 
Delegations  
Ensure an appropriate level of EU and MS 
funding and expertise to further strengthen 
and support third countries' efforts in 
addressing and preventing illicit drug crop 
cultivation, through rural development 
measures, in order to deal with the 
challenges to public health, safety and 
security  
 
 
Ongoing MS 
EEAS 
COM 
 Number of third country 
national policies, strategies 
and action plans that 
incorporate integrated 
approaches to the problem 
of illicit drug crop 
cultivation 
 Improvements in human 
development indicators in 
drug-cultivating areas 
 Number of rural 
EU and MS 
Project and 
Programme 
Monitoring 
and 
Evaluation 
Systems and 
Reports 
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Objective Action Timetable Responsible 
party 
Indicator(s) Data 
collection/ 
assessment 
mechanisms  
development projects and 
programmes, funded by the 
EU and MS in regions 
where illicit crop cultivation 
is taking place, or in regions 
at risk of illicit crop 
cultivation   
 Reported local decrease in 
illicit drug crop cultivation 
in the long-term 
 
 
UNDP 
Human 
Development 
Reports 
 
Third country 
reports  
35.  Promote and implement the EU 
approach to alternative development 
(consistent with the EU Drugs Strategy 
2013-2020; the EU Approach to 
Alternative Development and the United 
Nations Guiding Principles on 
Alternative Development 2013) in co-
operation with third countries, taking 
into account human rights, human 
security and specific framework 
conditions, including: 
 
a. incorporating alternative 
development into the broader agenda 
of Member States, encouraging third 
countries that wish to do so to 
integrate alternative development 
into their national strategies; 
Ongoing 
 
MS 
COM 
EEAS 
 
 Number of third country 
national policies, strategies 
and action plans that 
incorporate:  
o integrated approaches 
to the problem of 
illicit drug cultivation 
and  
o effectively organised 
alternative 
development 
initiatives  
 Number of evaluated 
projects that demonstrate 
positive outcomes relating 
to sustainable, legal and 
gender sensitive livelihoods 
 Improvements in human 
Third 
countries’ 
implementati
on reports of 
National 
Drugs 
Strategies 
 
 
EU and MS 
Project and 
Programme 
Monitoring 
and 
Evaluation 
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Objective Action Timetable Responsible 
party 
Indicator(s) Data 
collection/ 
assessment 
mechanisms  
b. contributing to initiatives that aim to 
reduce poverty, conflict and 
vulnerability by supporting 
sustainable, legal and gender 
sensitive livelihoods for people who 
were previously, or are currently, 
involved in illicit drug  production  
c. providing an appropriate level of 
EU and MS funding and expertise 
to further strengthen and support 
non-EU countries' efforts in 
addressing and preventing illicit 
drug crop cultivation, through 
rural development measures and 
illicit drug production through law 
enforcement and judicial 
cooperation 
development indicators 
 Number of rural 
development projects and 
programmes, funded by 
the EU and MS in regions 
where illicit crop 
cultivation is taking place, 
or in regions at risk of 
illicit crop cultivation   
 Reported local decrease in 
illicit drug crop 
cultivation in the long-
term 
 
 
Reports 
 
UNDP 
Human 
Development 
Reports 
 
Non-EU 
country 
reports 
36.  Support third countries, including civil 
society in those countries, to develop 
and implement risk and harm reduction 
initiatives particularly where there is a 
growing threat of transmission of drug-
related blood borne viruses associated 
with drug use including but not limited 
to HIV and viral hepatitis, as well as 
sexually transmittable diseases and 
tuberculosis 
Ongoing MS 
COM 
EEAS 
 Number and quality of risk 
and harm reduction 
initiatives developed 
 Prevalence of drug-related 
deaths in third countries  
and drug-related blood 
borne viruses  including but 
not limited to HIV and viral 
hepatitis, as well as sexually 
transmittable diseases and 
tuberculosis  
Third country 
Reports 
 
COM 
Biennial 
Progress 
Report 
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Objective Action Timetable Responsible 
party 
Indicator(s) Data 
collection/ 
assessment 
mechanisms  
WHO 
Reports   
37.  Support third countries to tackle drug-
related organised crime, including drug 
trafficking, by: 
a. intelligence-sharing and the 
exchange of best practices; 
b. strengthening counter-narcotics 
capacity and developing expertise of 
source and  transit countries; 
c. working with international partners 
to tackle the enablers of drug 
trafficking such as corruption, weak 
institutions, poor governance and 
lack of financial regulatory controls;  
d. strengthening co-operation in the 
field of asset identification and 
recovery, in particular through the 
creation of dedicated national 
platforms; and 
e. intensifying regional and intra-
regional co- operation 
f. incorporating rule-of-law and 
international human rights 
standards and principles in drug-
related law enforcement measures 
Ongoing 
 
MS 
EEAS 
COM 
Europol 
S 
 Number and effectiveness 
of projects and programmes 
 Sustained reduction in drug 
trafficking  
COM 
Biennial 
Progress 
Report 
 
COM and 
MS 
Reporting  
 
Europol 
Reporting 
 
EEAS 
Reporting 
 
UNODC 
Annual 
World Drug 
Report 
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Objective Action Timetable Responsible 
party 
Indicator(s) Data 
collection/ 
assessment 
mechanisms  
 38.  (a) Reinforce co-operation and conduct 
update and implement dialogues, 
Declarations and EU Drugs Action Plans 
with partners, including: 
  Acceding countries, candidate countries 
and potential candidates 
  European Neighbourhood Policy 
countries 
  United States of America, the   
 Russian Federation 
  Other countries or regions of priority 
notably: 
o Afghanistan and Pakistan  
o Central Asian Republics 
o China 
o Latin American and the Caribbean 
(CELAC) 
o Africa, in particular West Africa 
o Iran 
 
(b) Explore possibilities for engagement 
(such as bilateral dialogues, joint 
projects) with other non-EU countries on 
serious drug-related issues  
Ongoing PRES Trio 
COM 
EEAS 
MS 
 
 Overarching indicator 13 
 Strengthened co-operation 
in the field of drugs with 
relevant partners  
 Dialogues organised 
 Declarations agreed  
 Programmes and Action 
Plans implemented 
 
EEAS 
Reporting 
 
Mid-Term 
Review of 
EU Drugs 
Strategy 
 
 
COM 
Biennial 
Progress 
Report  
 
EU Reporting 
Matrices  
 
Implementati
on Reports of 
the relevant 
action plans  
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Objective Action Timetable Responsible 
party 
Indicator(s) Data 
collection/ 
assessment 
mechanisms  
39.  Improve the Dublin Group consultative 
mechanism through intensified EU 
coordination and participation, better 
formulation, implementation and 
dissemination of its recommendations of 
the Mini Dublin Group reports 
Ongoing Dublin Group 
COM 
EEAS 
MS 
 Level of activity across 
Dublin Group structures 
including number of Dublin 
Group recommendations 
effectively implemented 
 Achieved modernisation 
of the Dublin Group’s 
working methods 
Dublin Group 
Reports 
Hold an annual dialogue on EU and MS 
drugs-related assistance to third countries 
accompanied by a written update  
 
From 
2014  
 
COM 
EEAS 
MS 
 
 Annual dialogue on funding 
held  
 
COM  
Biennial 
Progress 
Report   
 
MS 
Reporting 
 
EEAS 
Reporting 
 
Project and 
Programme 
Monitoring 
and 
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Objective Action Timetable Responsible 
party 
Indicator(s) Data 
collection/ 
assessment 
mechanisms  
Evaluation 
System and 
Reports 
40.  Ensure that the promotion and 
protection of human rights are fully 
integrated in political dialogues and in 
the planning and implementation of 
relevant drugs-related programmes and 
projects including through the 
implementation of the rights-based 
approach (RBA)  and of tailored  
human rights guidance and impact 
assessment tool  
 
Ongoing COM 
EEAS 
MS 
 Human rights effectively 
mainstreamed into EU 
external drugs action 
 Human rights guidance and 
assessment tool developed 
and implemented 
 
COM 
Biennial 
Progress 
Report 
 
COHOM 
Annual 
Human 
Rights Report 
 
MS 
Reporting 
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Objective Action Timetable Responsible 
party 
Indicator(s) Data 
collection/ 
assessment 
mechanisms  
12. Improve 
cohesiveness of 
EU approach and 
EU visibility  in 
the United Nations 
(UN) and 
strengthen EU co-
ordination with 
international 
bodies related to 
the drugs field 
41.  Contribute to shaping the agenda on 
international drugs policy, including 
through:  
a. action by EU and MS Delegations at 
the UN General Assembly and the 
Commission on Narcotic Drugs 
(CND); 
b. action by EU and MS delegations 
in all UN fora addressing drug-
related matters (e.g. the UN 
General Assembly, World Health 
Assembly, Human Rights Council, 
High Level Political Forum on 
Sustainable Development)  
c. preparation, co-ordination and 
adoption of EU common positions 
and joint resolutions  in the UN 
General Assembly and the CND, 
including, ahead of the CND, on 
scheduling of substances, and 
ensuring that the EU speaks with one 
strong voice in these and other 
international fora; 
d. the implementation of the   
recommendations of the 2016 
UNGASS Outcome Document  
e.  the 2019 review process of the 2009 
UN Political Declaration and Action 
Plan on International Cooperation 
towards an Integrated and Balanced 
Ongoing EEAS 
PRES 
MS 
COM 
Council 
Council WP 
(HDG) 
 Overarching indicator 13 
 Number of EU statements 
delivered at CND and UN 
fora 
 Number of EU common 
positions supported by other 
regions and international 
bodies 
 Number of EU common 
positions concerning CND 
decisions on scheduling of 
substances 
 Outcome of the CND 
decisions on scheduling of 
substances 
 Frequency with which EU 
speaks with a single 
effective voice in 
international fora and in 
dialogues with third 
countries 
 Level of successful 
adoption  of EU resolutions 
at UN including at the CND 
 Effective promotion of EU 
policies in the UN, including 
at the CND 
 Adoption of an EU 
EEAS 
Reporting  
 
Mid-Term 
Review of 
the EU Drugs 
Strategy 
 
COM 
Biennial 
Progress 
Report  
 
Convergence 
Indicator  
 
Mid-term 
Review 
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Objective Action Timetable Responsible 
party 
Indicator(s) Data 
collection/ 
assessment 
mechanisms  
Strategy to Counter the World Drug 
Problem; and 
f. ensure the meaningful involvement 
of civil society in the review 
process 
 
Common Position Paper 
for the 2019 review 
process; EU contribution 
to the definition by the 
CND on the modalities for 
the 2019 process 
 Outcome of the 2019 
review of the UN Political 
Declaration and Action Plan 
on International Co-
operation towards an 
Integrated and Balanced 
Strategy to Counter the 
World Drug Problem 
UNGASS  
2019 review 
Outcome 
42.  Strengthen partnerships with the 
UNODC, WHO, UNAIDS and other 
relevant UN agencies, international and 
regional bodies and organisations and 
initiatives (such as the Council of 
Europe and the Paris Pact Initiative)  
Ongoing Council 
EEAS 
COM 
PRES 
Council WP 
(HDG) 
EMCDDA 
 
 Overarching indicators 13, 
15 
 Number of information 
exchanges and activities 
between the EU and 
relevant international and 
regional bodies and 
organisations and initiatives 
 Effectiveness of 
partnerships with relevant 
bodies 
EEAS 
Reporting  
 
Mid Term 
Review of 
the EU Drugs 
Strategy 
 
COM 
Biennial 
Progress 
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Objective Action Timetable Responsible 
party 
Indicator(s) Data 
collection/ 
assessment 
mechanisms  
Report  
 
13. Support the 
process for 
acceding countries, 
candidate 
countries, and 
potential 
candidates to adapt 
to and align with 
the EU acquis in 
the drugs field, 
through targeted 
assistance and 
monitoring 
43.  Provide targeted technical assistance, 
and other assistance and support as 
necessary, to acceding countries, 
candidate countries, and potential 
candidates to facilitate their adaptation 
to and alignment with the EU acquis in 
the drugs field  
 
Ongoing COM 
MS 
EMCDDA 
Europol 
Eurojust 
FRONTEX 
EEAS 
 Overarching indicator 15 
 Increased compliance by 
countries with EU acquis 
 Number and quality of 
completed projects 
 National Drugs Strategies 
and national drugs co-
ordinating structures 
established 
COM 
Biennial 
Progress  
Report  
 
Acceding 
countries, 
candidate 
countries and 
potential 
candidates 
reports 
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5. INFORMATION, RESEARCH, MONITORING AND EVALUATION 
Contribute to a better understanding of all aspects of the drugs phenomenon and of the impact of measures in order to provide sound and 
comprehensive evidence for policies and actions 
Objective Action Timetable Responsible 
party 
Indicator(s) Data 
collection/ 
assessment 
mechanisms  
14. Ensure 
adequate 
investment in 
research, data 
collection, 
monitoring, 
evaluation and  
information 
exchange on all 
aspects of the 
drug 
phenomenon  
44. Promote appropriate financing of EU-
level drug-related multi-disciplinary 
research and studies including through 
EU related financial programmes (2014-
2020) 
2017-2020 MS 
COM 
EMCDDA 
 
 Amount and type of EU 
funding provided across the 
different programme and 
projects 
COM  
reporting 
at annual 
research 
dialogue 
Biennial 
Progress 
Report  
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Objective Action Timetable Responsible 
party 
Indicator(s) Data 
collection/ 
assessment 
mechanisms  
 45.  Ensure that EU-supported projects:  
a. take account of the priorities of the  
EU Drugs Strategy and Action Plan 
on Drugs; 
b. take account of gaps in policy 
formulation; 
c. deliver clear added value and ensure 
coherence and synergy; and  
d. avoid duplication with research 
under other programmes and bodies 
e. take account of the importance of 
behavioural research and 
neuroscience
64
  
f. include clear indicators for 
measuring their impact 
 
 
2017-2020 COM 
EMCDDA 
 The inclusion of the priorities 
of the EU Strategy and Action 
Plan on Drugs in the funding 
and assessment criteria of EU-
funded drugs related research  
 Number, impact, 
complementarity and value of 
EU-funded drugs related 
research grants and contracts 
awarded  
 Number of EU-funded drugs 
related articles and research 
reports published in peer-
reviewed journals with high 
impact factors 
 Annual debate at the HDG on 
drug- related research projects 
funded by the EU including 
EMCDDA Scientific 
Committee 
recommendations on 
research priorities   
 
COM 
Biennial 
Progress 
Report  
 
Research 
project 
reports 
 
EMCDDA 
Scientific 
Committee 
recommendat
ions on 
research 
priorities 
 
Science 
Citation 
Index and 
similar 
bibliometric 
                                                            
64  Under Horizon 2020 (2014-2020), some €27 million have already been allocated to projects addressing drug addiction and include behavioural research and neuroscience 
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Objective Action Timetable Responsible 
party 
Indicator(s) Data 
collection/ 
assessment 
mechanisms  
tools 
 
Strategic 
research 
agenda 
developed by 
ERANID  
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Objective Action Timetable Responsible 
party 
Indicator(s) Data 
collection/ 
assessment 
mechanisms  
 46.  Promote scientific evidence-based 
evaluations of policies and interventions 
at national, EU and international level 
2017-2020 COM 
MS 
EMCDDA 
 
 Overarching indicator 14 
 Regular progress review to the 
Council and European 
Parliament on Strategy and 
Action Plan implementation 
 Number of countries 
following a structured 
approach, as outlined in the 
guide to commissioning and 
managing evaluations 
produced by the EMCDDA 
 External mid-term assessment 
of the Strategy/Action Plan 
completed – 2016 
 European guidelines for the 
evaluation of national drug 
strategies and action plans 
published 
 Delivery of dedicated studies 
into the effectiveness and 
impacts of EU and 
international drug policies 
 Completed evaluation of the 
implementation of the 2003 
Council Recommendation on 
the prevention and reduction 
of health-related harm 
associated with drug 
dependence 
EMCDDA 
Reporting 
 
COM 
Biennial 
Progress 
Report  
 
Mid-term 
Assessment 
Report of EU 
Drugs 
Strategy 
 
EMCDDA 
Reporting  
 
EMCDDA 
Scientific 
Committee 
Reporting 
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Objective Action Timetable Responsible 
party 
Indicator(s) Data 
collection/ 
assessment 
mechanisms  
 
Reports of 
Alice RAP 
and 
LINKSCH 
and ERA-net   
 
Reitox 
National 
Reports 
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Objective Action Timetable Responsible 
party 
Indicator(s) Data 
collection/ 
assessment 
mechanisms  
 47. Gather evidence of  potential 
connections between drugs trafficking 
and: 
 
a. financing of terrorist groups and 
activities, including any overlap 
between the established routes for 
drug production and trafficking 
areas and conflict zones; and 
financing sources of terrorist cells 
in the EU from illicit activities, 
including drug trafficking; 
b. migrant smuggling building 
synergies with the EU Action Plan 
against migrant smuggling (2015-
2020) that foresees research and 
risk analysis between smuggling 
and other crimes such as drugs 
trafficking and including: 
 A focus on vulnerable migrants 
and their potential exploitation 
for drugs trafficking purposes 
and/or as end users of drugs, in 
particular minors and women. 
 Exploration of any overlap 
between drugs trafficking and 
migrant smuggling criminal 
rings, modi operandi and routes.  
2017-2020 MS 
Commission 
EU ATC 
EMCDDA 
Europol 
Frontex 
FRA 
EIGE 
 Number of projects funded 
at EU and national level 
MS 
reporting 
COM 
reporting 
EU agencies 
reporting 
(EMCDDA 
Europol 
FRONTEX 
and FRA in 
the 
framework 
of their 
regular 
reporting 
activities 
EIGE in the 
framework 
of their 
regular 
reporting 
activities 
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Objective Action Timetable Responsible 
party 
Indicator(s) Data 
collection/ 
assessment 
mechanisms  
c. trafficking in human beings 
building synergies with the EU 
legal and policy framework 
addressing trafficking in human 
beings including the EU Strategy 
towards the Eradication of 
Trafficking in Human Beings 
2012–2016 
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Objective Action Timetable Responsible 
party 
Indicator(s) Data 
collection/ 
assessment 
mechanisms  
15. Maintain 
networking and 
co-operation 
and develop 
capacity within 
and across the 
EU’s 
knowledge 
infrastructure 
for information, 
research, 
monitoring and 
evaluation of 
drugs, 
particularly 
illicit drugs 
48. In collaboration with relevant parties as 
appropriate, continue to provide 
comprehensive analyses of: 
a. the EU drugs situation; 
b. the dynamics of drug use within 
general populations and target 
groups including ethnic minorities, 
migrants and asylum seekers, 
LGBTI, commercial sex workers 
and prisoners; and 
c.  responses to drug use 
d. EU and international 
developments relating to cannabis 
policy models and their impacts 
 Ongoing   
 
 
 
 
 
 
EMCDDA 
Europol  
MS 
 
Civil Society 
Forum on 
Drugs 
 
COM 
 Overarching indicators 1-15   
 Current deficits in the 
knowledge base established 
and an EU level framework 
developed to maximise 
analyses from current data 
holdings  
 Number of overviews and 
topic analyses on the drug 
situation 
EMCDDA 
Reporting 
 
MS 
Reporting 
 
Civil Society 
Forum on 
Drugs 
 
COM 
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Objective Action Timetable Responsible 
party 
Indicator(s) Data 
collection/ 
assessment 
mechanisms  
49.  Enhance training for those involved in 
responding to the drugs phenomenon 
2017-2020                MS
EMCDDA 
CEPOL 
 Number of initiatives at MS 
and EU level to train 
professionals in aspects of 
drug demand reduction and 
drug supply reduction 
 Number of initiatives at MS 
and EU level implemented to 
train professionals  related to 
data collection and reporting 
of drug demand reduction and 
drug supply reduction 
MS 
Reporting 
 
EMCDDA 
Training 
Report 
 
CEPOL 
Annual 
Report 
 
Reitox 
Annual 
Reports 
50.  Enhance data collection, research, 
analysis and reporting  on:  
a. drug demand reduction;  
b. drug supply reduction;  
c. emerging trends, such as polydrug 
use and misuse of prescribed 
controlled psychoactive medicines,  
that pose risks to health and safety;  
d. blood borne viruses associated with 
drug use including but not limited to 
Ongoing MS 
COM 
EMCDDA 
Europol 
ECDC 
 Increased availability and 
implementation of evidence-
based and scientifically sound 
indicators on drug supply 
reduction and drug demand 
reduction 
 At MS level, extent of new 
research initiated on emerging 
trends such as polydrug use 
and the misuse of prescribed 
EMCDDA 
Reporting 
 
MS 
Reporting 
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Objective Action Timetable Responsible 
party 
Indicator(s) Data 
collection/ 
assessment 
mechanisms  
HIV and viral hepatitis, as well as 
sexually transmittable diseases and 
tuberculosis; 
e. psychiatric and physical co-
morbidity;  
f. drug problems among prisoners and 
the availability and coverage of drug 
demand reduction interventions and 
services in prison settings; and 
g. other drug-related consequences 
problems and consequences 
related both to licit and illicit 
substances  
h. compliance of drugs policies with 
international human rights 
standards and principles 
EMA 
  
controlled medicines;  blood 
borne diseases associated with 
drug use including but not 
limited to HIV and viral 
hepatitis, as well as sexually 
transmittable diseases and 
tuberculosis; psychiatric and 
physical co-morbidity; and 
other drug-related 
consequences 
 EU-wide study carried out on 
drug-related community 
intimidation and its impact on 
individuals, families and 
communities most affected and 
effective responses to it 
 Adoption of evidence-based 
and scientifically sound 
indicators on  drug problems 
among prisoners  
Harmonised 
data reports 
from EU 
bodies 
including 
EMCDDA 
 
 
 
EU SOCTA  
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Objective Action Timetable Responsible 
party 
Indicator(s) Data 
collection/ 
assessment 
mechanisms  
51.  Improve the capacity to detect, assess 
and respond effectively to the emergence 
and use of new psychoactive substances 
and monitor the extent to which such 
new substances impact on the number 
and profile of users 
 
Ongoing COM 
MS 
EMCDDA 
Europol 
 
 Overarching indicator 6 
 Extent of new 
epidemiological, 
pharmacological and 
toxicological research initiated 
on new psychoactive 
substances and supported by 
MS and EU Research 
programmes 
 Extent of information, best 
practice and intelligence 
exchange 
 Extent of sharing by 
toxicology laboratories and by 
Research Institutes of 
toxicological and health data 
analyses on new psychoactive 
substances 
 
EMCDDA 
Reporting 
 
EMCDDA-
Europol 
Implementati
on Report 
 
Reports by 
laboratories 
and research 
institutes 
 
Reitox 
National 
Reports  
52.  Strengthen efforts to share forensic 
science data, including support on the 
identification of new psychoactive 
substances, laboratory reference 
standards on new psychoactive 
substances, and the development of a 
common methodology for the 
identification of new substances by 
2017-2020 COM 
MS 
EMCDDA 
 
 Overarching indicator 15 
 Extent of sharing of forensic 
science data on new 
psychoactive substances, 
supporting the identification 
of new psychoactive 
substances  
 Ease of access to laboratory 
EMCDDA/ 
Europol 
Reporting 
 
COM 
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Objective Action Timetable Responsible 
party 
Indicator(s) Data 
collection/ 
assessment 
mechanisms  
enhancing co-operation with the 
Commission's Joint Research Centre, 
and through existing networks, such as 
the Drugs Working Group of the 
European Network of Forensic Science 
Institutes in the framework of the JHA 
Council Conclusions on the Vision for 
European Forensic Science 2020 and 
the Customs Laboratories European 
Network 
reference standards by forensic 
science laboratories, customs 
laboratories and institutes 
 Progress on development of 
a common methodology for 
the identification of new 
psychoactive substances 
reporting 
 
COM 
Biennial 
Progress 
Report 
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Objective Action Timetable Responsible 
party 
Indicator(s) Data 
collection/ 
assessment 
mechanisms  
 53.  Improve the ability to identify, assess 
and respond at MS and EU levels to (a) 
behavioural changes in drug 
consumption and (b) to drug-related 
epidemic outbreaks 
Ongoing MS 
EMCDDA 
ECDC 
EMA 
 Number and effectiveness of 
new drug-related public health 
initiatives developed and 
implemented 
 Number and effectiveness of 
existing initiatives that are 
adjusted to take account of 
drug consumption or epidemic 
outbreaks 
 Number and impact of early 
warning reports, risk 
assessment and alerts 
Reitox 
National 
Reports 
 
Early 
Warning 
System 
reports 
 
EMCDDA 
Reporting 
16. Enhance 
dissemination 
of monitoring, 
research and 
evaluation 
results at EU 
and national 
level  
54.  Member States continue to support EU 
monitoring and information exchange 
efforts, including co-operation with, and 
adequate support for, Reitox National 
Focal Points 
Ongoing MS 
 
EMCDDA 
 
COM 
 Open-access outputs from EU 
funded studies disseminated  
 Extent to which Reitox 
National Focal Points funding 
and other resources match 
requirements 
 Number and effectiveness of 
Reitox National Focal Points 
dissemination initiatives 
Web 
Disseminatio
n including 
OpenAire, 
Cordis  
 
EMCDDA 
website  
Reitox 
National 
reports 
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6. ANNEX 1 - 15 OVER-ARCHING INDICATORS FOR THE EU ACTION PLAN ON DRUGS 2017-
2020
1
  
1. Percentage of population who use drugs currently (within last month), used drugs recently 
(within last year), and who have ever used (lifetime use) by drug and age group  (EMCDDA 
General Population Survey) 
2. Estimated trends in the prevalence of problem and injecting drug use (EMCDDA Problem 
Drug Use) 
3. Trends in drug induced deaths and mortality amongst drug users (according to national 
definitions)(EMCDDA Drug-related Deaths) 
4. Prevalence and incidence, among injecting drug users, of infectious diseases attributable to 
drug use, including HIV and viral Hepatitis, sexually transmittable diseases and tuberculosis  
(EMCDDA Drug-related Infectious Diseases) 
5. Trends in the age of first use of illicit drugs (European School Survey Project on Alcohol and 
Drugs (ESPAD), Health Behaviour in School-aged Children (HBSC) and General Population 
Drug Use Survey (EMCDDA Key Epidemiological Indicator)  
6. Trends in numbers of people entering drug treatment (EMCDDA Treatment Demand) and the 
estimated total number of people in drug treatment (EMCDDA Treatment Demand and 
Health and Social Responses) 
7. Trends in number of and quantities of seized illicit drugs (EMCDDA Drug Seizures: cannabis 
incl. herbal cannabis, heroin, cocaine, crack cocaine, amphetamine, methamphetamine,  
ecstasy, LSD and other substances) 
8. Trends in retail price and purity of illicit drugs (EMCDDA Price and Purity:  cannabis incl. 
herbal cannabis, heroin, cocaine, crack cocaine, amphetamine, methamphetamine, ecstasy, 
LSD, other substances and composition of drug tablets) 
9. Trends in the number of initial reports of drug law offences, by drug and type of offence 
(supply vs use/possession)(EMCDDA Drug Offences) 
10. Prevalence of drug use amongst prisoners (EMCDDA Drug Use in Prisons) 
11. Assessment of availability, coverage and quality of services and interventions in the areas of 
prevention, harm reduction, social integration and treatment. (EMCDDA Health and Social 
Responses) 
12. Evidence based interventions on prevention,  treatment, social integration and recovery and 
their expected impact on drug use prevalence and problem drug use (EMCDDA Best Practice 
Portal) 
13. Strong dialogue and co-operation, in the drugs related field, with other regions, third 
countries, international organisations and other parties (External Mid-Term Evaluation of 
Strategy/Action Plan; EEAS reporting) 
14. Developments in national drug strategies, evaluations, legislation, co-ordination mechanisms 
and public expenditure estimates in EU Member States (EMCDDA) 
15. Early Warning System on new psychoactive substances (EMCDDA/Europol) and Risk 
Assessment on new psychoactive substances (EMCDDA) 
                                                            
1  These indicators are based on existing reporting systems that pre-date the objectives of the current EU drug 
strategy and action plan, but provide the most comprehensive set of EU level resources to support their 
monitoring and evaluation 
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7. ANNEX 2 - GLOSSARY OF ACRONYMS 
Alice RAP
  
Addiction and Lifestyles in Contemporary Europe Reframing Addictions 
Project 
ASEAN Association of Southeast Asian Nations 
CCWP Council of the EU - Customs Cooperation Working Party  
CELAC
  
Comunidad de Estados Latinoamericanos y Caribeños (Community of Latin 
American and Caribbean States) 
CEPOL European Police College 
CICAD La Comisión Interamericana para el Control del Abuso de Drogas (The Inter-
American Drug Abuse Control Commission 
CND Commission on Narcotic Drugs (UN)  
COAFR Council of the EU - Africa Working Party 
COASI Council of the EU - Asia-Oceania Working Party 
COEST Council of the EU - Working Party on Eastern Europe and Central Asia 
COHOM Council of the EU - Working Party on Human Rights 
COLAT Council of the EU - Working Party on Latin America 
COM European  Commission 
CONUN    Council of the EU – United Nations Working Party  
COSI Council of the EU - Standing Committee on Operational Cooperation on 
Internal Security  
Council WP      Council Working Party 
COWEB Council of the EU - Working Party on the Western Balkans Region 
CUG Council of the EU - Customs Union Group 
ECDC European Centre for Disease Control 
ECOWAS Economic Community of West African States 
EEAS European Union External Action Service 
EMA European Medicines Agency 
EMCDDA European Monitoring Centre for Drugs and Drug Addiction 
EMPACT  European Multidisciplinary Platform against Criminal Threats 
ENFSI European Network of Forensic Science Institutes 
ERA-net European Research Area – Network 
ERANID European Research Area Network on Illicit Drugs  
ESPAD European School Survey Project on Alcohol and Drugs 
EU   European Union 
EUROJUST  European Judicial Cooperation Unit 
EUROPOL   European Union Agency for Law Enforcement Cooperation 
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EU SOCTA EU Serious and Organised Crime Threat Assessment 
FRONTEX European Agency for the Management of Operational Cooperation at the 
External Borders of the Member States of the European Union 
HBSC Health Behaviour in School Aged Children survey 
HCV    Hepatitis C virus 
HDG Council of the EU - Horizontal Working Group on Drugs 
HIV Human immunodeficiency virus 
INCB International Narcotics Control Board (UN) 
JHA Justice and Home Affairs 
LGBTI    Lesbian, Gay, Bisexual, Transgender/Transsexual and Intersexed 
LSD   Lysergic acid diethylamide 
MASPs   Multi-annual Strategic Plans (Europol) 
MOU Memorandum of Understanding 
LINKSCH  The LINKSCH project is a comparative study of two major drug markets, 
cannabis and heroin, through the prism of the transit chains operating between 
Central Asia and the EU and those between North Africa and the EU 
MS  Member State 
NPS 
PEN 
New psychoactive substances 
UNODC/INCB developed Pre-Export Notification Online System 
PICS Precursors Incident Communication System 
PRES Rotating Presidency of the Council of the European Union 
PRES Trio Grouping of three consecutive rotating Presidencies of the Council of the 
European Union 
Reitox Réseau Européen d’Information sur les Drogues et les Toxicomanies 
SOCTA Serious and Organised Crime Threat Assessment 
UN  United Nations 
UNAIDS Joint United Nations Programme on HIV/AIDS 
UNGASS United Nations General Assembly Special Session 
UNODC United Nations Office on Drugs and Crime 
UNDP   United Nations Development Programme 
WCO World Customs Organisation 
WHO World Health Organisation (UN) 
 
